Unique CDR3 epitope targeting by CAR-T cells is a viable approach for treating T-cell malignancies

被引：0

作者：

Jinqi Huang

Stepanov Alexey

Jian Li

Terri Jones

Geramie Grande

Lacey Douthit

Jun Xie

Danna Chen

Xiaolei Wu

Maschan Michael

Changchun Xiao

Jiangning Zhao

Xuehua Xie

Jia Xie

Xiao Lei Chen

Guo Fu

Gabibov Alexander

Chi-Meng Tzeng

机构：

[1] Xiamen University,Translational Medicine Research Center (TMRC), School of Pharmaceutical Sciences

[2] The Scripps Research Institute,Department of Chemistry

[3] Russian Academy of Sciences,M.M. Shemyakin and Yu.A. Ovchinnikov Institute of Bioorganic Chemistry

[4] Xiamen University,State Key Laboratory of Cellular Stress Biology, Innovation Center for Cell Signaling Network, School of Life Sciences

[5] The Affiliated Hospital of Putian University,Department of Immunology and Microbiology

[6] ProteinT Biotechnology Ltd. Co. Tianjin Airport Free Trade Zone,Department of Hematology

[7] Dmitrii Rogachev Federal Research Center for Pediatric Hematology,Department of Oncology

[8] Oncology and Immunology,School of Pharmacology

[9] The Scripps Research Institute,undefined

[10] zhongshan Hospital of Xiamen University,undefined

[11] The first hospital of Putian City,undefined

[12] Nanjing Tech University,undefined

来源：

Leukemia | 2019年 / 33卷

关键词：

D O I：

暂无

中图分类号：

学科分类号：

摘要：

引用

页码：2315 / 2319

页数：4

共 50 条

[41] Secondary malignancies after CAR-T cell therapy
Lorenz, Judith
DEUTSCHE MEDIZINISCHE WOCHENSCHRIFT, 2024, 149 (22) : 1312 - 1313
[42] An "off-the-shelf" CD2 universal CAR-T therapy for T-cell malignancies
Xiang, Jingyu
Devenport, Jessica M.
Carter, Alun J.
Staser, Karl W.
Kim, Miriam Y.
O'Neal, Julie
Ritchey, Julie K.
Rettig, Michael P.
Gao, Feng
Rettig, Garrett
Turk, Rolf
Lee, Byung Ha
Cooper, Matthew L.
DiPersio, John F.
LEUKEMIA, 2023, 37 (12) : 2448 - 2456
[43] An “off-the-shelf” CD2 universal CAR-T therapy for T-cell malignancies
Jingyu Xiang
Jessica M. Devenport
Alun J. Carter
Karl W. Staser
Miriam Y. Kim
Julie O’ Neal
Julie K. Ritchey
Michael P. Rettig
Feng Gao
Garrett Rettig
Rolf Turk
Byung Ha Lee
Matthew L. Cooper
John F. DiPersio
Leukemia, 2023, 37 : 2448 - 2456
[44] Targeting T-cell malignancies using allogeneic double-negative CD4-CAR-T cells
Fang, Karen Kai-Lin
Lee, Jongbok
Khatri, Ismat
Na, Yoosu
Zhang, Li
JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2023, 11 (09)
[45] Treating Acute Leukemia with CAR-T cell and antibodies
Ehninger, Gerhard
BONE MARROW TRANSPLANTATION, 2018, 53 : 813 - 813
[46] A T-CELL RECEPTOR (TCR) CDR3 PEPTIDE SHOWING ENHANCING EFFECTS ON EAE
YAMAMURA, T
GENG, TC
KOZOVSKA, M
TABIRA, T
NEUROLOGY, 1994, 44 (04) : A241 - A241
[47] Conserved T-cell receptor β chain CDR3 sequences in IgA nephropathy biopsies
Wu, HL
Zhang, GY
Clarkson, AR
Knight, JF
KIDNEY INTERNATIONAL, 1999, 55 (01) : 109 - 119
[48] Preclinical development of bispecific CAR-T cells for canine B cell malignancies
Atherton, Matthew J.
Rotolo, Antonia
Mason, Nicola J.
CANCER RESEARCH, 2022, 82 (12)
[49] MOLECULAR ANALYSIS OF THE HELPER T-CELL RESPONSE IN MURINE INTERSTITIAL NEPHRITIS - T-CELLS RECOGNIZING AN IMMUNODOMINANT EPITOPE USE MULTIPLE T-CELL RECEPTOR V-BETA GENES WITH SIMILARITIES ACROSS CDR3
HEEGER, PS
SMOYER, WE
SAAD, T
ALBERT, S
KELLY, CJ
NEILSON, EG
JOURNAL OF CLINICAL INVESTIGATION, 1994, 94 (05): : 2084 - 2092
[50] Advances in CAR-T-cell therapy in T-cell malignancies
Zheng, Rubing
Zhu, Xiaojian
Xiao, Yi
JOURNAL OF HEMATOLOGY & ONCOLOGY, 2024, 17 (01)

← 1 2 3 4 5 →